NEW YORK, June 27 (GenomeWeb News) - Fluidigm announced today it has secured series E funding from AllianceBernstein.
The company plans to use the money to develop and commercialize new applications for its proprietary integrated fluidic circuits technology, which has applications in genomics and proteomics.
Fluidigm's BioMark system uses IFCs for genetic and protein analysis, and the company said that it is developing further IFC-based systems "for rapid synthesis of radio-labeled imaging probes and preparation of nucleic acids for analysis."
Fluidigm declined to disclose the amount of the funding.